Abstract: In one aspect, adaptive replication modes in a storage system are provided. An aspect includes during an active replication session in which a first type of replication is performed at the storage system, monitoring write input/output (IO) operations, collecting data from the write IO operations, and determining, from the collected data, write IO latency. Upon determining that a threshold value has been met from the write IO latency, where the threshold value is defined for the first type of replication, an aspect includes automatically switching from the first type of replication to a second type of replication. The second type of replication is configured to compensate for operational deficiencies detected in response to the write IO latency.

Abstract: The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

Abstract: In a data processing method for an immersive media, independently coded region description information of an independently coded region of the immersive media is acquired. The independently coded region corresponds to a segmented video of a plurality of segmented videos encapsulated in tracks of a same track group. The independently coded region description information includes an independently coded region information and coordinate information. The coordinate information includes coordinate system identification information that indicates a coordinate system of the independently coded region. Further, the segmented video of the immersive media is displayed according to the independently coded region description information. Apparatus and non-transitory computer-readable storage medium counterpart embodiments are also contemplated.

Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

Abstract: Techniques described herein perform spherical PIP analysis by detecting whether a test ray (defined by a test point (TP) and a point (EP) that is external to a spherical polygon) crosses edge arcs (“edges”) of the polygon based on relative orientations of vertices of the test ray and edges. A classifier vector (CV) for a test ray is calculated based on the cross-product of the TP and the EP. Using the CV, the orientation of each vertex of the polygon with respect to the test ray is determined. Candidate edges having vertices with opposite orientations with respect to the test ray are identified. Crossing edges are determine by calculating CVs for each candidate edge, and determining orientations of the TP and EP with respect to each candidate edge. A set of crossing edges is determined, where the TP and the EP have opposite orientations with respect to each crossing edge.

Abstract: In a data processing method for immersive media, metadata of the immersive media is obtained. The metadata includes (i) zoom region information of a zoom region of the immersive media, and (ii) zoom mode information that indicates whether a target zoom mode is enabled for the zoom region. The zoom mode information indicates zoom parameters of the target zoom mode for the zoom region when the target zoom mode is enabled. Zoom processing is performed on the zoom region of the immersive media according to the zoom mode information included in the metadata when the zoom mode information indicates that the target zoom mode is enabled for the zoom region. Apparatus and non-transitory computer-readable storage medium counterpart embodiments are also contemplated.

Abstract: A high-resolution processing method for seismic data based on inverse multi-resolution singular value decomposition includes the steps of: step 1: obtaining a single-trace seismic signal X as a raw signal; step 2: decomposing the seismic signal by using MRSVD algorithm to obtain a series of detailed singular values and inversely recursing the detailed singular values layer by layer to obtain a new detailed signal and an approximate signal; and step 3: sequentially superimposing the new detailed signal on the raw signal, layer by layer, to compensate the high-frequency component of the seismic signal so as to obtain a high-resolution seismic signal.

Abstract: A method for providing immersive media, performed by at least one processor includes adding resolution description information and resolution selection strategy information to file format information of immersive media content, determining a target resolution to be provided to a client based on the resolution description information and the resolution selection strategy information of the immersive media content, and transmitting an immersive media file of the target resolution to the client.

Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.

Abstract: The invention provides methods to prepare protein conjugates from proteins having at least two cysteines. In one embodiment, a protein with a disulfide linkage is reduced to provide two free cysteines for reaction with a 1,3-dihaloacetone or similar reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form a Schiff base to an aminated payload molecule, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant. The linkage between the sulfur atoms in each case holds the protein or peptide in a constrained conformation, while also providing a convenient place for attaching a payload with good specificity and efficiency.

Abstract: The present disclosure provides methods of treating subjects having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, and methods of detecting Angiopoietin-Like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides.

Abstract: The invention provides compositions and methods containing alpha-helical polypeptides as permeation enhancers for effectuating the passage of therapeutic agents into the inner ear by passage through the round window membrane. Examples of permeation-enhancing peptides useful in conjunction with the compositions and methods described herein are facially amphipathic, positively charged peptides. The permeation-enhancing peptides of the disclosure may be used to effectuate the entry of a variety of therapeutic agents into the inner ear, such as proteins, antibodies, nucleic acids, viral vectors, and nanoparticles, among others. Upon accessing the inner ear, the therapeutic agents may migrate to a particular site at which they may exert their biological effect.

Abstract: Various aqueous coating formulations are described. The compositions include one or more UV curable polyurethane dispersions, and optionally one or more of the following: non-UV curable acrylic polymers, a polyester dispersion, a non-UV curable polyurethane dispersion, and one or more additives. The compositions can be used to form top coats that exhibit good resistance to scratches and solvents, and improved ink adhesion and image quality.

Abstract: A method is disclosed comprising: generating a first snapshot of a first storage subsystem; detecting, by a management node, that all in-flight data storage requests recorded in drain tables of storage nodes in the first storage subsystem have been completed, the in-flight data storage requests recorded in the drain tables of the storage nodes being replicated in a second storage subsystem; causing, by the management node, each of the storage nodes to flip the respective designations of the tracking tables in the node's respective pair of tracking tables; and transmitting, from the management node to the second storage subsystem, an instruction which when received by the second storage subsystem causes the second storage subsystem to generate a second snapshot of the second storage subsystem.

Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.

Abstract: The present invention discloses a dynamic straightening method for a left/right tilt. The method includes: drawing an unevenness curve according to a distance from a shapemeter to a surface of a plate, where there are a plurality of unevenness curves; using a barycentric formula to obtain a first barycentric coordinate of each unevenness curve; calculating a tilt value of a straightening roll corresponding to each unevenness curve according to the first barycentric coordinate of each unevenness curve; determining an unevenness curve of a current straightening roll; adjusting the straightening roll according to the tilt value of the straightening roll corresponding to the unevenness curve, to straighten the plate; and going back to the step of determining an unevenness curve of a current straightening roll until the plate is totally straightened. The present invention improves plate straightening accuracy by dynamically adjusting parameters of the straightening roll.

Abstract: Various aqueous coating formulations are described. The compositions include one or more UV curable polyurethane dispersions, and optionally one or more of the following: non-UV curable acrylic polymers, a polyester dispersion, a non-UV curable polyurethane dispersion, and one or more additives. The compositions can be used to form top coats that exhibit good resistance to scratches and solvents, and improved ink adhesion and image quality.

Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.

Abstract: This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.

Abstract: This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.